← Back to Search

Bypassing Agent

Treatment for Hemophilia A

Phase 4
Waitlist Available
Led By Guy Young, MD
Research Sponsored by Children's Hospital Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the goal is to complete all study procedures within 12 months.
Awards & highlights

Study Summary

This trial will study the in vivo combination of Feiba in patients with inhibitors on emicizumab, in order to see if it is effective in preventing breakthrough bleeding.

Eligible Conditions
  • Hemophilia A

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the goal is to complete all study procedures within 12 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the goal is to complete all study procedures within 12 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Thrombin generation

Find a Location

Who is running the clinical trial?

Children's Hospital Los AngelesLead Sponsor
232 Previous Clinical Trials
5,076,748 Total Patients Enrolled
4 Trials studying Hemophilia A
77 Patients Enrolled for Hemophilia A
TakedaIndustry Sponsor
1,202 Previous Clinical Trials
4,178,242 Total Patients Enrolled
12 Trials studying Hemophilia A
7,133 Patients Enrolled for Hemophilia A
Guy Young, MDPrincipal Investigator - professor
Children's Hospital Los Angeles
SuNew York At StoNew York Brook Hlth Sci Center (Medical School)
Children'S Natl Medical Center (Residency)
3 Previous Clinical Trials
101 Total Patients Enrolled
1 Trials studying Hemophilia A
52 Patients Enrolled for Hemophilia A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab
Guy Young 2020. "A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04205175.
All > Hemophilia A > Hemophilia
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top